This pilot trial studies how well escitalopram works in treating cognitive dysfunction in patients with grade IV glioma and grade III astrocytoma. Escitalopram is a drug used treat depression and certain anxiety disorders and may help to improve brain function and mood in patients with glioma.
Additional locations may be listed on ClinicalTrials.gov for NCT03728673.
Locations matching your search criteria
United States
Nebraska
Omaha
University of Nebraska Medical CenterStatus: Active
Contact: Nicole Annette Shonka
Phone: 402-559-3881
PRIMARY OBJECTIVES:
I. To characterize the degree of change in neural measures of cognition / brain function in grade IV glioma and grade III IDH wild-type astrocytoma patients associated with 17 weeks of treatment with an selective serotonin reuptake inhibitor (SSRI).
II. To determine the degree of change in psychosocial function, as assessed via ratings in mood and quality of life, in grade IV glioma and grade III IDH wild-type astrocytoma patients after 17 weeks of treatment of SSRI.
EXPLORATORY OBJECTIVE:
I. To evaluate whether changes in mood during the trial will negatively correlate with electroencephalography (EEG) and cognitive measures of brain function after 17 weeks of treatment of an SSRI.
OUTLINE:
Patients receive escitalopram orally (PO) once daily (QD) for 17 weeks in the absence of unacceptable toxicity. Patients undergo magnetic resonance imaging (MRI), and blood sample collection throughout the study.
Lead OrganizationUniversity of Nebraska Medical Center
Principal InvestigatorNicole Annette Shonka
